Description Chronic pelvic pain associated with numerous conditions of the pelvic area (endometriosis, interstitial cystitis, recurrent cystitis, chronic prostatitis, irritable bowel syndrome, etc.) is a clinical entity with a dual location, resulting from neuro-inflammatory phenomena sustained by non-neuronal cells (mast cells, microglia). The tissue location, linked to peripheral sensitisation of the sensory endings of nerves that co-innervate different pelvic organs, determines the share of widespread inflammatory pain and the associated oxidative stress. The spinal location, linked instead to central sensitisation arising from the chronic nature of the peripheral neuro-inflammatory phenomenon, determines and sustains the share of neuropathic pain that amplifies the pain perceived by the patient.
Pelvilen Dual Act can act effectively on both components of pain (mixed pain) through a synergistic and synchronous regulating effect exerted by palmitoylethanolamide in two forms, micronised and ultra-micronised. The simultaneous presence of polydatin, a polyphenol with high antioxidant activity, allows control of the oxidative stress associated with neuro-inflammation in the pelvic tissues.
Ingredients Co-micronised palmitoylethanolamide-polydatin (particle size 2.0-10.0 microns), ultra-micronised palmitoylethanolamide (particle size 0.8-6.0 microns); emulsifiers: microcrystalline cellulose, magnesium salts of fatty acids, vegetable polysorbate, E1521; stabilisers: croscarmellose sodium, polyvinylpyrrolidone, polyvinyl alcohol; anti-caking agents: silicon dioxide, talc; colourings: E132, E171, E172.
Gluten-free.
Nutritional information | Average values | per 1 tablet | per 100 g |
| Energy | 7.13 kcal
29.9 kJ | 631 kcal
2,642 kJ |
| Protein | <0.01 g | <1.0 g |
Carbohydrate
of which sugars | <0.01 g | <1.0 g |
Fat
of which saturates | 0.79 g
0.68 g | 70.0 g
60.0 g |
| Fibre | 0.20 g | 17.5 g |
| Salt | 0.014 g | 1.25 g |
| Palmitoylethanolamide | 0.800 g | 70.8 g |
| Polydatin | 0.040 g | 3.54 g |
Directions for use Pelvilen Dual Act, in its two different formulations (microgranules for sublingual use and tablets), must be used under medical supervision. Recommended use:
-Pelvilen Dual Act microgranules, preferably taken sublingually, on medical advice, as a guide 1-2 sachets a day for cycles of at least 10 days, repeated if necessary.
-Pelvilen Dual Act tablets, on medical advice, as a guide 1-2 tablets a day for cycles of 20-30 days, repeated if necessary.
Warnings Use under medical supervision.
The products cannot be the sole source of nutrition.
Keep out of the reach of children under 3 years of age.
Use of the products is not recommended during pregnancy.
Storage Store at room temperature.
Shelf life in intact packaging: 36 months.
Pack size Blister of 20 tablets.
Code 8026
